Lilly to shift more employees to Covance
Greenfield Labs operation expects to add 17 Eli Lilly and Co. workers after taking over staff of 264 in 2008 acquisition.
Greenfield Labs operation expects to add 17 Eli Lilly and Co. workers after taking over staff of 264 in 2008 acquisition.
With President Barack Obama looking to squeeze a bit more revenue out of the pharmaceutical industry, the stakes just keep
getting higher for Eli Lilly and Co.’s efforts to develop drugs faster and cheaper.
Dr. Judy Monroe will end a five-year run as Indiana state commissioner of health on March 8. She will become
deputy director of the U.S. Centers for Disease Control and Prevention, overseeing communication between federal and state
public health agencies. Until Gov. Mitch Daniels names a replacement, Monroe’s deputy, Loren Robertson, will fill her
shoes.
Community Heart and Vascular, a unit of Community Health Network, named Kevin Fowler chief financial officer.
Fowler, who earned his MBA at Indiana State University, has been the CFO at Lubbock Heart Hospital in Texas since 2007.
Community Heart and Vascular hired two electrophysiologists, Dr. Chad Bonhomme and Dr. Krishna Malineni,
along with Dr. Shalabh Singhal, an invasive cardiologist. The unit of Community Health Network has now hired
eight physicians in the past year.
OrthoWorx, a Warsaw-based group focused on advancing the city’s orthopedics implant industry, named Cheryl
Blanchard as its chairperson. Blanchard is chief scientific officer at Warsaw-based Zimmer Holdings Inc.
Bloomington-based Cook Pharmica promoted Veda Walcott to be its vice president of quality and corporate
compliance officer. Walcott has worked for Cook Pharmica since 2005 after stints at Cook Medical and Baxter BioPharma Solutions.
Dr. Richard Aina, an internist who focuses on chronic diseases, has joined St. Vincent Physician Network
in Indianapolis. Aina received his medical degree from the University of Illinois College of Medicine in Champaign, Ill.
Duane M. Schmitz, a former executive at Eli Lilly and Co., has joined Indianapolis-based Harrison College
as president of its online division. Nearly half of the for-profit school’s students take at least one course online.
Drug developer Transition Therapeutics Inc. said Wednesday that it will pay $1 million to license a group of potential diabetes
drugs from Eli Lilly and Co.
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
Dr. Gregory N. Larkin, the former global medical director at Eli Lilly and Co., will replace Dr. Judy Monroe, who is leaving
to become deputy director of the Centers for Disease Control and Prevention.
The investment will greatly expand the company’s research and development capacity and is a major win for the Indiana
life sciences industry. Dow AgroSciences expects most of the positions to pay between $65,000 and $95,000 annually.
Agricultural biotech firm hired a site-selection consultant and considered other cities around the world for its $340 million
expansion.
Gov. Mitch Daniels should step through the door he cracked open last month and throw
his hat in the ring. Voters would benefit from a new voice.
Out of six professionals IBJ profiled a year ago, three have found jobs, although all have accepted lower pay than
they were getting before. One could not be reached, but she still lists herself as looking for work on LinkedIn.com. Two tried
to start their own businesses, with one giving up and one, Bruce Flanagan, still trying.
Lilly Endowment’s resistance to diversify its holdings reached a new height last year, as it failed to sell a single share
of the underperforming Eli Lilly and Co. stock while the broader market surged.
Brightpoint, WellPoint and Cummins are recognized by Fortune magazine as being among the best in their industries.
The acquisition will benefit Elanco, Lilly’s animal health division in Greenfield, which has become increasingly important
to Lilly as it braces for patent-protection losses.
Two of the five most-advertised drugs belong to hometown drugmaker Eli Lilly and Co. According to 2009 data from The Nielsen Co., Lilly spent $178 million to advertise Cymbalta, its antidepressant and pain medicine, and another $167 million to hawk Cialis, its anti-impotence pills. Those two drugs ranked No. 4 and No. 5, respectively. They […]
With President Obama looking to squeeze a bit more revenue out of the pharmaceutical industry, the stakes just keep getting higher for Eli Lilly and Co.’s efforts to develop drugs faster and cheaper. Lilly is already trying to shave a year or more off the time it takes the company’s scientists to turn a newly […]
Regulators won’t require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
Eli Lilly & Co., the maker of the impotence pill Cialis, bought exclusive rights from Australia’s Acrux Ltd. to
an underarm testosterone lotion called Axiron for men with limited sex drive due to low levels of the hormone.
Pharmaceuticals stolen Sunday morning could be worth up to $75 million.